Capital Market Strategies LLC Decreases Stock Position in Eli Lilly and Company $LLY

Key Points

• Capital Market Strategies LLC significantly reduced its stake in Eli Lilly and Company by 55.8%, now holding 1,446 shares valued at approximately $1.13 million.
• Despite this reduction, other institutional investors, such as Brighton Jones LLC and Breed’s Hill Capital LLC, increased their positions in the company, showcasing continued investor interest.
• Eli Lilly reported strong quarterly earnings, exceeding analyst expectations with $6.31 EPS and revenues of $15.56 billion, marking a 37.6% increase compared to the same quarter last year.

Capital Market Strategies LLC lowered its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 55.8% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,446 shares of the company's stock after selling 1,826 shares during the period. Eli Lilly and Company comprises about 0.8% of Capital Market Strategies LLC's holdings, making the stock its 27th largest position. Capital Market Strategies LLC's holdings in Eli Lilly and Company were worth $1,128,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the company. Hobbs Wealth Management LLC lifted its stake in Eli Lilly and Company by 0.8% in the first quarter. Hobbs Wealth Management LLC now owns 1,459 shares of the company's stock valued at $1,205,000 after buying an additional 12 shares during the last quarter. Hixon Zuercher LLC increased its holdings in shares of Eli Lilly and Company by 0.7% in the 1st quarter. Hixon Zuercher LLC now owns 1,789 shares of the company's stock valued at $1,477,000 after acquiring an additional 12 shares during the period. O Brien Wealth Partners LLC raised its position in Eli Lilly and Company by 25.5% in the 1st quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock valued at $49,000 after purchasing an additional 12 shares during the last quarter. Ascent Capital Management LLC boosted its stake in Eli Lilly and Company by 2.5% during the 1st quarter. Ascent Capital Management LLC now owns 495 shares of the company's stock worth $409,000 after purchasing an additional 12 shares during the period. Finally, Tennessee Valley Asset Management Partners grew its position in Eli Lilly and Company by 2.7% during the 1st quarter. Tennessee Valley Asset Management Partners now owns 493 shares of the company's stock worth $407,000 after purchasing an additional 13 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Eli Lilly and Company

In related news, Director Jamere Jackson purchased 200 shares of the business's stock in a transaction dated Friday, August 8th. The stock was acquired at an average price of $639.56 per share, for a total transaction of $127,912.00. Following the acquisition, the director directly owned 9,402 shares of the company's stock, valued at $6,013,143.12. This trade represents a 2.17% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director J Erik Fyrwald acquired 1,565 shares of the firm's stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the acquisition, the director owned 74,578 shares of the company's stock, valued at $47,903,686.74. This represents a 2.14% increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 4,514 shares of company stock worth $2,894,841. Company insiders own 0.14% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on LLY. Leerink Partners reiterated a "market perform" rating and set a $715.00 target price on shares of Eli Lilly and Company in a research note on Thursday, August 7th. Hsbc Global Res raised Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a research note on Wednesday, August 27th. Daiwa Capital Markets downgraded Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 target price on the stock. in a research note on Sunday, August 17th. UBS Group dropped their target price on Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating on the stock in a report on Friday, August 8th. Finally, Cantor Fitzgerald decreased their price target on Eli Lilly and Company from $975.00 to $825.00 and set an "overweight" rating for the company in a report on Wednesday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have given a Hold rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $941.35.

Eli Lilly and Company Stock Performance

NYSE LLY traded down $1.38 on Friday, hitting $754.90. 2,195,977 shares of the company's stock were exchanged, compared to its average volume of 3,436,359. The firm has a market cap of $714.48 billion, a price-to-earnings ratio of 49.34, a P/E/G ratio of 1.05 and a beta of 0.47. The firm's 50-day moving average price is $741.03 and its two-hundred day moving average price is $775.51. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $942.35. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. During the same period last year, the firm earned $3.92 EPS. The company's quarterly revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th were paid a dividend of $1.50 per share. The ex-dividend date of this dividend was Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.8%. Eli Lilly and Company's dividend payout ratio is 39.22%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.